ITGR

Business Context and Reporting Period

Company: Wilson Greatbatch Technologies, Inc. (Note: Request metadata listed "Integer Holdings Corp," but the filing text identifies the registrant as Wilson Greatbatch Technologies, Inc.)

Reporting Period: Fiscal year ended January 2, 2004 (referred to as December 31, 2003, in the text).

Business Overview: The Company operates two segments: Implantable Medical Components (IMC), providing batteries, capacitors, and components for implantable medical devices (IMDs) like pacemakers and defibrillators; and Electrochem Power Solutions (EPS), producing high-performance batteries for commercial applications including oil and gas, aerospace, and oceanography.

Key Financial Metrics

Material Changes vs. Prior Period

• Revenue Growth: Sales increased 29% to $216.4 million, driven primarily by the IMC segment (up 34%) due to strong demand for ICD batteries and capacitors. The EPS segment saw modest growth of 3%.
• Profitability: Net income rose 62% to $23.3 million. Operating margins improved to 17.7% from 15.5%, reflecting operating leverage despite a slight decline in gross margin (41.5% vs. 42.4%) due to consolidation costs and lower-margin enclosure products.
• Capital Structure: In May 2003, the Company issued $170.0 million in convertible subordinated notes. Proceeds were used to pay off a $72.5 million term loan and invest excess cash, significantly strengthening liquidity.
• Customer Concentration: The two largest customers (Guidant and St. Jude Medical) accounted for approximately 66% of total sales in 2003, consistent with 2002.

Guidance, Outlook, and Risks

Outlook: Management forecasts sales growth in 2004 to be lower than the double-digit growth experienced in the prior two years. The Company anticipates downward pricing pressures on some products but expects to expand operating margins through increased volume, infrastructure leverage, and manufacturing cost reductions.

Strategic Initiatives:

• Expansion of capacitor customer penetration (three of five global CRM manufacturers now use the technology).
• Delivery of next-generation "Quasar" battery technology by year-end 2004.
• Completion of a company-wide ERP system implementation.
• Continued investment in R&D and potential acquisitions.

Risks and Contingencies:

• Customer Dependence: Heavy reliance on a limited number of customers; loss of a major customer could materially impact results.
• Supply Chain: Reliance on a limited number of suppliers for critical raw materials; inability to quickly qualify new suppliers.
• Intellectual Property: Reliance on licensed technology (e.g., wet tantalum capacitors from Evans Capacitor Company); cancellation of licenses could impair production.
• Regulatory: While components are not directly FDA regulated, customer products are; changes in reimbursement guidelines or FDA approvals affect demand.

Investor Verification Checklist

• Convertible Note Terms: Verify the conversion price and conditions for the $170 million convertible subordinated notes due 2013, as these could lead to significant equity dilution.
• Customer Contracts: Review the specific terms and renewal options of the supply agreements with Guidant and St. Jude Medical, which represent two-thirds of revenue.
• Margin Sustainability: Assess whether the projected margin expansion in 2004 can offset the noted downward pricing pressures and increased costs (Sarbanes-Oxley compliance, new facility build-out).
• Goodwill Valuation: Monitor the $119.5 million in goodwill for potential impairment, particularly given the reliance on specific technologies and customer relationships.
• Quasar Technology: Confirm the timeline and market reception of the new Quasar battery technology, a key driver for future growth.